The Author’s Reply

Jureidini J, Mintzes B, Raven M. Does direct-to-consumer advertising of antidepressants lead to a net social benefit? Pharmacoeconomics 2008; 26 (7): 557–66 Block AE. Costs and benefits of direct-to-consumer advertising: the case of depression. Pharmacoeconomics 2007; 25 (6): 511–21 US Department of Health and Human Services; US Food and Drug Administration. Revisions to product labeling for antidepressants. Rockville (MD): US FDA, 2007 [online]. Available from URL: http://www.fda.gov/CDER/DRUG/antidepressants/antidepressants_label_change_2007.pdf [Accessed 2008 Jun 4] Vos T, Haby MM, Barendregt JJ, et al. The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry 2004; 61: 1097–103 Paulson RH, Katon W, Ciechanowski P. Initial treatment of depression in adults [online]. Available from URL: http://www.uptodate.com/patients/content/topic.do?topicKey=psychiat/12876 [Accessed 2008 Feb 10] Trivedi MH, Rush AJ, Wisniewski SR, STAR*D study team, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163 (1): 28–40